MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Bridgebio Pharma Inc

Abrir

SetorSaúde

35.93 1.24

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.86

Máximo

35.96

Indicadores-chave

By Trading Economics

Rendimento

-103M

-267M

Vendas

3.2M

5.9M

EPS

-1.374

Margem de lucro

-4,545.886

Funcionários

725

EBITDA

-95M

-235M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+57.87% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-334M

6.4B

Abertura anterior

34.69

Fecho anterior

35.93

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Bridgebio Pharma Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

12 de set. de 2024, 17:01 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 de set. de 2024, 11:00 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Bridgebio Pharma Inc Previsão

Preço-alvo

By TipRanks

57.87% parte superior

Previsão para 12 meses

Média 56.77 USD  57.87%

Máximo 95 USD

Mínimo 46 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

15

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

34.24 / 36.11Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.